Bradley Foster & Sargent’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$42.2M Buy
35,186
+8,118
+30% +$8.29M 0.6% 47
2026
Q1
$24.9M Buy
27,068
+877
+3% +$889K 0.39% 59
2025
Q4
$28.1M Buy
26,191
+468
+2% +$447K 0.41% 55
2025
Q3
$19.6M Buy
25,723
+652
+3% +$485K 0.29% 79
2025
Q2
$19.5M Buy
25,071
+722
+3% +$561K 0.31% 77
2025
Q1
$20.1M Buy
24,349
+4,656
+24% +$3.87M 0.34% 73
2024
Q4
$15.2M Sell
19,693
-930
-5% -$770K 0.26% 86
2024
Q3
$18.3M Buy
20,623
+442
+2% +$397K 0.31% 76
2024
Q2
$18.3M Buy
20,181
+558
+3% +$446K 0.33% 68
2024
Q1
$15.3M Buy
19,623
+723
+4% +$515K 0.28% 80
2023
Q4
$11M Sell
18,900
-2,418
-11% -$1.41M 0.21% 96
2023
Q3
$10M Hold
21,318
0.21% 88
2023
Q2
$10M Buy
21,318
+373
+2% +$156K 0.21% 88
2023
Q1
$7.19M Sell
20,945
-55
-0.3% -$18.5K 0.17% 100
2022
Q4
$7.68M Buy
21,000
+156
+0.7% +$55.3K 0.19% 88
2022
Q3
$6.74M Buy
20,844
+14
+0.1% +$4.44K 0.19% 89
2022
Q2
$6.75M Buy
20,830
+463
+2% +$139K 0.17% 96
2022
Q1
$5.83M Buy
20,367
+3,801
+23% +$978K 0.12% 126
2021
Q4
$4.58M Buy
16,566
+625
+4% +$158K 0.09% 137
2021
Q3
$3.68M Sell
15,941
-4,348
-21% -$1.07M 0.09% 139
2021
Q2
$4.66M Sell
20,289
-450
-2% -$90.4K 0.11% 124
2021
Q1
$3.88M Sell
20,739
-12,100
-37% -$2.37M 0.1% 135
2020
Q4
$5.54M Sell
32,839
-50
-0.2% -$7.46K 0.15% 109
2020
Q3
$4.87M Buy
+32,889
New +$5.09M 0.14% 108
2020
Q1
$4.66M Buy
33,579
+734
+2% +$101K 0.19% 98
2019
Q4
$4.32M Buy
32,845
+111
+0.3% +$12.9K 0.13% 123
2019
Q3
$3.66M Sell
32,734
-165
-0.5% -$18.4K 0.12% 128
2019
Q2
$3.65M Sell
32,899
-231
-0.7% -$27.2K 0.12% 124
2019
Q1
$4.3M Buy
33,130
+172
+0.5% +$20.9K 0.15% 119
2018
Q4
$3.81M Sell
32,958
-3,570
-10% -$399K 0.15% 115
2018
Q3
$3.92M Hold
36,528
0.13% 129
2018
Q2
$3.12M Sell
36,528
-100
-0.3% -$8.21K 0.11% 144
2018
Q1
$2.83M Buy
36,628
+1,123
+3% +$90.4K 0.11% 144
2017
Q4
$3M Sell
35,505
-53
-0.1% -$4.51K 0.11% 139
2017
Q3
$3.04M Sell
35,558
-265
-0.7% -$21.7K 0.12% 136
2017
Q2
$2.95M Buy
35,823
+404
+1% +$33K 0.12% 130
2017
Q1
$2.98M Sell
35,419
-1,029
-3% -$82.4K 0.12% 126
2016
Q4
$2.68M Buy
36,448
+1,455
+4% +$108K 0.11% 133
2016
Q3
$2.81M Sell
34,993
-100
-0.3% -$8K 0.12% 122
2016
Q2
$2.76M Hold
35,093
0.12% 120
2016
Q1
$2.53M Sell
35,093
-883
-2% -$66.8K 0.12% 121
2015
Q4
$3.03M Sell
35,976
-250
-0.7% -$20.7K 0.14% 124
2015
Q3
$3.03M Sell
36,226
-1,225
-3% -$103K 0.15% 121
2015
Q2
$3.13M Sell
37,451
-1,703
-4% -$130K 0.14% 126
2015
Q1
$2.85M Sell
39,154
-172
-0.4% -$12.2K 0.13% 130
2014
Q4
$2.71M Buy
39,326
+225
+0.6% +$15.2K 0.13% 131
2014
Q3
$2.54M Buy
39,101
+9,900
+34% +$627K 0.12% 139
2014
Q2
$1.81M Sell
29,201
-3,645
-11% -$217K 0.09% 153
2014
Q1
$1.93M Hold
32,846
0.1% 141
2013
Q4
$1.68M Sell
32,846
-208
-0.6% -$10.4K 0.09% 151
2013
Q3
$1.66M Sell
33,054
-134
-0.4% -$7.01K 0.1% 142
2013
Q2
$1.63M Buy
+33,188
New +$1.81M 0.1% 134

Other funds holding LLY

Bradley Foster & Sargent's LLY Position: Q2 2026 in Review

Bradley Foster & Sargent increased its Eli Lilly (LLY) stake by 30% in Q2 2026, buying an estimated $8.29M and bringing the position to 35,186 shares worth $42.2M. The position accounts for 0.6% of the portfolio, ranked #47.

Bradley Foster & Sargent first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Bradley Foster & Sargent held 35,186 shares of Eli Lilly worth $42.2M as of Q2 2026.
  • Bradley Foster & Sargent bought 8,118 Eli Lilly shares in Q2 2026, an estimated $8.29M.
  • Eli Lilly made up 0.6% of Bradley Foster & Sargent's portfolio in Q2 2026, its #47 holding.
  • Bradley Foster & Sargent first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Bradley Foster & Sargent's 13F filing for Q2 2026, filed 14 Aug 2026.